Tirzepatide has quickly become one of the most effective medications available for weight management, and at IVUSE+ it is prescribed and managed entirely through async telehealth by licensed clinicians. Here is how it works, what the clinical evidence shows, and how treatment works at IVUSE+.
What is tirzepatide?
Tirzepatide is a once-weekly injectable medication that activates two gut-hormone receptors at once: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Most earlier weight-management medications target only GLP-1. By engaging both pathways, tirzepatide influences appetite, blood sugar, and how the body processes food through a dual mechanism.
How tirzepatide supports weight loss
Tirzepatide helps in several complementary ways:
- It reduces appetite and quiets the constant food noise that drives cravings.
- It slows gastric emptying, so you feel full longer after meals.
- It improves the body's insulin response and blood-sugar control.
- Paired with adequate protein and resistance training, it supports fat loss while helping preserve muscle.
Because it works on appetite and satiety rather than willpower alone, it makes sustainable diet and activity changes easier to maintain.
What the clinical evidence shows
In the SURMOUNT-1 trial, adults with obesity or overweight lost an average of 20.9% of their body weight on the 15 mg dose over 72 weeks, with up to 22.5% in the per-protocol analysis.[1] That places tirzepatide among the most effective weight-management medications studied to date. A later head-to-head trial, SURMOUNT-5, compared the two directly and found tirzepatide produced greater average weight loss than semaglutide (20.2% versus 13.7% over 72 weeks).[4] This is consistent with semaglutide's own pivotal STEP-1 trial, which showed about 14.9% over 68 weeks.[2] Both are highly effective; the right choice depends on the individual. If you are weighing the two options, our guide on semaglutide vs. tirzepatide walks through the differences.
How treatment works at IVUSE+
At IVUSE+, compounded tirzepatide is prescribed only after a licensed clinician reviews your health history through a confidential online assessment. If treatment is appropriate, your medication is prepared by a licensed 503A/503B compounding pharmacy and shipped to you, and your clinician adjusts your dose over time as you progress. Pricing is flat and transparent at $360 per month, with medication, telehealth consultation, and shipping included. There is no membership fee and no subscription.
Is tirzepatide right for you?
Tirzepatide is powerful, but it is not appropriate for everyone. Certain medical conditions and medications make it unsuitable, and side effects, most commonly mild to moderate nausea during dose increases, should be discussed with your clinician. Review the full tirzepatide safety information before starting, and share your complete medical history, including any contraception you use, since tirzepatide can reduce the absorption of oral birth control.
Getting started
If you are ready to explore tirzepatide, you can learn more about compounded tirzepatide and complete a confidential online assessment. A licensed clinician reviews every request before any prescription is issued.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). New England Journal of Medicine. 2021;384:989-1002.
- Mounjaro (tirzepatide) Prescribing Information, Eli Lilly and Company.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine. 2025;392:2225-2237.
This article is for general education and is not medical advice. Compounded medications are not FDA-approved. A telehealth consultation with a licensed clinician is required before any prescription is issued.
